Current Therapeutic Strategies for Hepatocellular Carcinoma in Japan

Current Therapeutic Strategies for Hepatocellular Carcinoma in Japan

Bibliographic Details
Main Author:	Masatoshi Kudo
Format:	Article
Language:	English
Published:	Karger Publishers 2023-10-01
Series:	Liver Cancer
Subjects:	hepatocellular carcinoma atezolizumab plus bevacizumab abc conversion therapy len-tace sequential therapy
Online Access:	https://beta.karger.com/Article/FullText/534304

Similar Items

Changing the Treatment Paradigm for Hepatocellular Carcinoma Using Atezolizumab plus Bevacizumab Combination Therapy
by: Masatoshi Kudo
Published: (2021-10-01)

The impact of curative conversion therapy aimed at a cancer‐free state in patients with hepatocellular carcinoma treated with atezolizumab plus bevacizumab
by: Shigeo Shimose, et al.
Published: (2023-06-01)

Therapeutic Modifications without Discontinuation of Atezolizumab Plus Bevacizumab Therapy Are Associated with Favorable Overall Survival and Time to Progression in Patients with Unresectable Hepatocellular Carcinoma
by: Takayuki Tokunaga, et al.
Published: (2023-03-01)

Prioritized Requirements for First-Line Systemic Therapy for Hepatocellular Carcinoma: Broad Benefit with Less Toxicity
by: Masatoshi Kudo
Published: (2023-01-01)

Two cases of unresectable hepatocellular carcinoma treated via atezolizumab and bevacizumab combination therapy
by: Ryosuke Tsunemitsu, et al.
Published: (2023-06-01)

Pretreatment Proteinuria Predicts the Prognosis of Patients Receiving Systemic Therapy for Unresectable Hepatocellular Carcinoma
by: Kazuyuki Mizuno, et al.
Published: (2023-05-01)

Adverse events as potential predictive factors of therapeutic activity in patients with unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab
by: Toshifumi Tada, et al.
Published: (2023-04-01)

Initial therapeutic results of atezolizumab plus bevacizumab for unresectable advanced hepatocellular carcinoma and the importance of hepatic functional reserve
by: Tetsu Tomonari, et al.
Published: (2023-02-01)

Implications of the TACTICS Trial: Establishing the New Concept of Combination/Sequential Systemic Therapy and Transarterial Chemoembolization to Achieve Synergistic Effects
by: Masatoshi Kudo
Published: (2022-10-01)

First-Line Atezolizumab Plus Bevacizumab versus Sorafenib in Hepatocellular Carcinoma: A Cost-Effectiveness Analysis
by: Chi-Leung Chiang, et al.
Published: (2021-02-01)

Efficacy of the Combination of Systemic Sequential Therapy and Locoregional Therapy in the Long-Term Survival of Patients with BCLC Stage C Hepatocellular Carcinoma
by: Yusuke Kawamura, et al.
Published: (2023-07-01)

Does first‐line treatment have prognostic impact for unresectable HCC?—Atezolizumab plus bevacizumab versus lenvatinib
by: Atsushi Hiraoka, et al.
Published: (2023-01-01)

Clinical Features and Outcomes of Conversion Therapy in Patients with Unresectable Hepatocellular Carcinoma
by: Tetsu Tomonari, et al.
Published: (2023-10-01)

Similar efficacy and safety between lenvatinib versus atezolizumab plus bevacizumab as the first‐line treatment for unresectable hepatocellular carcinoma
by: Chung‐Wei Su, et al.
Published: (2023-03-01)

Transarterial Chemoembolization Combined with Atezolizumab Plus Bevacizumab or Lenvatinib for Unresectable Hepatocellular Carcinoma: A Propensity Score Matched Study
by: Zhao C, et al.
Published: (2023-07-01)

Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios as Prognostic Biomarkers in Unresectable Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab
by: Yue Linda Wu, et al.
Published: (2022-11-01)

Outcomes and Toxicities of Modern Combined Modality Therapy with Atezolizumab Plus Bevacizumab and Radiation Therapy for Hepatocellular Carcinoma
by: Gohar Shahwar Manzar, et al.
Published: (2022-04-01)

Outcome of Atezolizumab Plus Bevacizumab Combination Therapy in High-Risk Patients with Advanced Hepatocellular Carcinoma
by: Sang Youn Hwang, et al.
Published: (2024-02-01)

Cost-effectiveness analysis of sorafenib, lenvatinib, atezolizumab plus bevacizumab and sintilimab plus bevacizumab for the treatment of advanced hepatocellular carcinoma in China
by: Hongyu Gong, et al.
Published: (2023-03-01)

Immunotherapy of advanced hepatocellular carcinoma: case report and literature review
by: K. V. Menshikov, et al.
Published: (2022-06-01)

Safety and efficacy of atezolizumab plus bevacizumab in elderly patients with hepatocellular carcinoma: A multicenter analysis
by: Toshifumi Tada, et al.
Published: (2022-10-01)

Safety and Feasibility of Combining On-Demand Selective Locoregional Treatment with First-Line Atezolizumab Plus Bevacizumab for Patients with Unresectable Hepatocellular Carcinoma
by: Tasuku Nakabori, et al.
Published: (2024-03-01)

Treatment Strategy for Intermediate-Stage Hepatocellular Carcinoma: Transarterial Chemoembolization, Systemic Therapy, and Conversion Therapy
by: Takeshi Hatanaka, et al.
Published: (2023-03-01)

Usefulness of Tumor Marker Score for Predicting the Prognosis of Hepatocellular Carcinoma Patients Treated with Atezolizumab Plus Bevacizumab: A Multicenter Retrospective Study
by: Kazunari Tanaka, et al.
Published: (2023-08-01)

Feasibility of additional radiotherapy in patients with advanced hepatocellular carcinoma treated with atezolizumab plus bevacizumab
by: Tae Hyun Kim, et al.
Published: (2023-09-01)

Analysis of Lenvatinib’s Efficacy against Intermediate-Stage Unresectable Hepatocellular Carcinoma
by: Kei Amioka, et al.
Published: (2022-10-01)

Atezolizumab/Bevacizumab vs. Lenvatinib as First-Line Therapy for Unresectable Hepatocellular Carcinoma: A Real-World, Multi-Center Study
by: Beom Kyung Kim, et al.
Published: (2022-03-01)

Initial Experience of Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma in Real-World Clinical Practice
by: Hideki Iwamoto, et al.
Published: (2021-06-01)

Efficacy and safety of atezolizumab plus bevacizumab in patients with portal hypertension for unresectable hepatocellular carcinoma
by: Takahiro Kinami, et al.
Published: (2024-03-01)

Thyroid Dysfunction after Atezolizumab and Bevacizumab Is Associated with Favorable Outcomes in Hepatocellular Carcinoma
by: Young Shin Song, et al.
Published: (2023-05-01)

Effect of butyrate‐producing enterobacteria on advanced hepatocellular carcinoma treatment with atezolizumab and bevacizumab
by: Kazuhiro Nouso, et al.
Published: (2023-09-01)

The New Era of Systemic Treatment for Hepatocellular Carcinoma: From the First Line to the Optimal Sequence
by: Maria Cerreto, et al.
Published: (2023-09-01)

High serum IL-6 correlates with reduced clinical benefit of atezolizumab and bevacizumab in unresectable hepatocellular carcinoma
by: Hannah Yang, et al.
Published: (2023-04-01)

Immune-Based Combinations versus Sorafenib as First-Line Treatment for Advanced Hepatocellular Carcinoma: A Meta-Analysis
by: Alessandro Rizzo, et al.
Published: (2023-01-01)

Favorable response of hepatocellular carcinoma with portal vein tumor thrombosis after radiotherapy combined with atezolizumab plus bevacizumab
by: Yong Tae Kim, et al.
Published: (2023-03-01)

Atezolizumab plus bevacizumab-induced intratumoral hemorrhage in a patient with rib metastasis from unresectable hepatocellular carcinoma
by: Yasuhito Mitsuyama, MD, et al.
Published: (2023-09-01)

Current hepatocellular carcinoma systemic pharmacological treatment options
by: A. Caturano, et al.
Published: (2023-05-01)

Efficacy and Safety of Atezolizumab and Bevacizumab in the Real-World Treatment of Advanced Hepatocellular Carcinoma: Experience from Four Tertiary Centers
by: Vera Himmelsbach, et al.
Published: (2022-03-01)

A case of successful surgical treatment for peritoneal seeding of hepatocellular carcinoma after radiotherapy and atezolizumab plus bevacizumab combination treatment
by: Yuri Cho, et al.
Published: (2023-03-01)

Hyperprogressive disease during atezolizumab plus bevacizumab treatment in patients with advanced hepatocellular carcinoma from Japanese real-world practice
by: Sae Yumita, et al.
Published: (2023-03-01)